---
title: "Anaphylaxis Research - Ayel L. R. Batac"
title-block: false
format:
  html:
    toc: false
    anchor-links: false
    include-in-header: 
      text: |
        <title>Anaphylaxis Research - Ayel L. R. Batac</title>
        <meta name="description" content="Evidence synthesis research on anaphylaxis in clinical immunology and public health." />
        <meta name="keywords" content="anaphylaxis, allergy, food allergy, clinical immunology, epinephrine, glucocorticoids, China, evidence synthesis, scoping review, public health, global health, research, Ayel Batac, epidemiologist" />
---

# ANAPHYLAXIS

$~$

Anaphylaxis is a **life-threatening allergic reaction** that requires rapid recognition and immediate treatment with intramuscular **epinephrine**. Despite the availability of clinical guidelines and growing global awareness, the **treatment of anaphylaxis remains inconsistent**, particularly in low-resource settings and underserved regions. Barriers—including limited access to epinephrine, diagnostic delays, and inadequate emergency response systems—continue to drive preventable morbidity and mortality worldwide.

$~$

## Understanding Global Variation in Anaphylaxis Treatment

There is growing recognition of **global variation** in how anaphylaxis is treated across different healthcare systems. While epinephrine is the recommended first-line treatment, evidence shows it remains under-utilized worldwide, with antihistamines and glucocorticoids often used instead in emergency and acute care settings. This variation may be influenced by differences in clinical training, national guidelines, healthcare infrastructure, or cultural practices.

Our current research is synthesizing global evidence on:

- **International differences** in anaphylaxis treatment and outcomes  
- **Access to epinephrine**, including auto-injectors (EAIs) and ampoules  
- **Alignment with clinical guidelines** across healthcare systems  
- **Barriers to timely care**, including regulatory, cost, and training constraints  

This research aims to characterize diverse treatment practices across global contexts. The findings are intended to inform **policy recommendations** that support more consistent, evidence-based emergency care for anaphylaxis worldwide.

$~$

## Anaphylaxis Treatment in China

In this work, I examined the introduction and integration of epinephrine auto-injectors (EAIs) in mainland China, highlighting several persistent challenges in a context where access had historically been limited:

- Outlined the evolving landscape of anaphylaxis management in China    
- Highlighted systemic barriers to EAI access and implementation  
- Identified gaps in clinical training and public awareness  
- Explored how global best practices may inform national protocols  
- Contributed to broader discussions on health equity and emergency preparedness  

This work underscores the need for sustained policy attention, enhanced clinical training, and system-level adaptation to expand access to life-saving anaphylaxis treatment and strengthen emergency preparedness.

$~$

## Contribution to Public Health

Anaphylaxis is both a clinical emergency and a public health concern. Our research addresses critical gaps in how anaphylaxis is recognized, treated, and prevented across diverse health systems. By examining variations in treatment practices and barriers to epinephrine access, this work informs strategies to reduce preventable morbidity and mortality on a population level.

Key public health contributions include:

- Generating evidence to support **policy and regulatory reform** on epinephrine access  
- Informing **training and education strategies** for clinicians, emergency responders, and the public  
- Identifying opportunities to **standardize emergency care protocols** in alignment with global best practices  
- Contributing to **health equity initiatives** by addressing disparities in access to life-saving treatment  
- Supporting **international collaboration** on anaphylaxis research and response planning  

This work aims to bridge clinical insight with system-level action, reinforcing the importance of coordinated, evidence-based approaches to allergy emergencies in public health planning and preparedness.

$~$

```{=html}
<p style="font-size: 1.5rem; font-weight: 600; color: #1B153E; margin-bottom: 1rem;">
  Featured Publication
</p>

<div style="display: flex; flex-wrap: wrap; gap: 2rem; align-items: flex-start; margin-top: 1.5rem;">

  <!-- Infographic Image -->
  <div style="flex: 0 0 400px;">
    <a href="https://doi.org/10.1111/cea.70028" target="_blank" rel="noopener noreferrer">
      <img src="eai_china.png" alt="Anaphylaxis Infographic - China" 
           style="width: 100%; border-radius: 8px; box-shadow: 0 4px 8px rgba(0,0,0,0.05); transition: transform 0.3s ease;"
           onmouseover="this.style.transform='scale(1.05)'" 
           onmouseout="this.style.transform='scale(1)'">
    </a>
  </div>

  <!-- Publication Description -->
  <div style="flex: 1; min-width: 250px;">

    <!-- Title -->
    <h3 style="font-weight: 600; color: #1B153E; margin: 0 0 1rem 0; font-size: 1.05rem;">
      From Ampoules to Auto-Injectors: Advancing Anaphylaxis Management in China
    </h3>

    <!-- Description -->
    <p>
      This publication examines the evolving landscape of anaphylaxis treatment in mainland China, with particular attention to the introduction of epinephrine auto-injectors. It highlights persistent challenges—including regulatory barriers, cost constraints, and limited provider awareness—and offers policy recommendations to support the integration of standardized, life-saving interventions into national emergency response systems.
    </p>

    <!-- Citation -->
    <p style="font-size: 0.70rem;">
      <a href="https://doi.org/10.1111/cea.70028" target="_blank" rel="noopener noreferrer" style="text-decoration: none; color: #1B153E;" onmouseover="this.style.color='#DE2221'" onmouseout="this.style.color='#1B153E'">
        <strong>Batac ALR.</strong> From Ampoules to Auto-Injectors: Advancing Anaphylaxis Management in China. Clin Exp Allergy. 2025 Mar 12. doi: 10.1111/cea.70028. PMID: 40071384.
      </a>
    </p>

  </div>
</div>
```

$~$

$~$

*Stay tuned — publications and data visualizations related to this work will be made available here soon.*

$~$

<small>
This research is conducted under my leadership in collaboration with physician and allied health partners in Canada, the United States, the United Kingdom, Japan, and Australia. It reflects a shared commitment to advancing evidence-based, patient-centred approaches to the prevention, recognition, and management of anaphylaxis.
</small>

<style>
  h1, h2, h3, p {
    color: #1B153E;
  }
</style>
